Silver Book Fact

Use of pneumonia vaccine in children reduced rates in adults age 65+

Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4; invasive pneumococcal disease rates in unvaccinated individuals age 65 and older fell by 18%.

Whitney C, Farley M, Hadler J, Harrison L, et al. Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine. NEJM. 2003; 348(18): 1737-46. http://www.nejm.org/doi/full/10.1056/NEJMoa022823

Reference

Title
Decline in Invasive Pneumococcal Disease After the Introduction of Protein-Polysaccharide Conjugate Vaccine
Publication
NEJM
Publication Date
2003
Authors
Whitney C, Farley M, Hadler J, Harrison L, et al
Volume & Issue
Volume 348, Issue 18
Pages
1737-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Effectiveness of pneumonia vaccine
    PPSV23 (pneumococcal polysaccharide vaccine) protects against 23 types of pneumococcal bacteria and is 60% to 80% effective in preventing pneumococcal bacteremia in adults over the age of 65 who are…  
  • Cost of measles much higher than vaccine
    One case of measles can cost 23 times as much as a single vaccination to prevent it.  
  • Vaccines in development 2013
    Vaccines in development for 2013  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.  
  • Use of shingles vaccine could save $82 to $103 million
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…